TL;DR — Creatine and ALS Research
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease, is a devastating neurodegenerative condition that progressively destroys motor neurons. Because ALS involves mitochondrial dysfunction and cellular energy failure in motor neurons, creatine — as a key player in cellular energy metabolism — was investigated as a potential neuroprotective agent. Preclinical studies in ALS mouse models showed promising results: creatine supplementation delayed disease onset, slowed progression, and improved survival. However, multiple large human clinical trials failed to demonstrate significant disease-modifying benefits. The ALS research experience provides important lessons about the challenges of translating preclinical neuroprotection into clinical outcomes, while also affirming creatine’s fundamental safety profile even in vulnerable patient populations.
Understanding ALS
ALS is a progressive neurodegenerative disease that selectively destroys motor neurons — the nerve cells in the brain and spinal cord that control voluntary muscle movement. As motor neurons die, patients progressively lose the ability to move, speak, swallow, and eventually breathe. The disease affects approximately 2 per 100,000 people globally, with most cases occurring between ages 55 and 75.
The pathophysiology of ALS involves multiple mechanisms:
Mitochondrial dysfunction — motor neurons in ALS patients show impaired mitochondrial function, leading to reduced ATP production and increased oxidative stress.
Excitotoxicity — excessive glutamate signaling damages motor neurons, partly due to energy failure that compromises the cells’ ability to regulate ion channels.
Oxidative stress — increased production of reactive oxygen species damages cellular components, including mitochondrial membranes and DNA.
Protein aggregation — abnormal protein deposits (including TDP-43 and SOD1 aggregates) accumulate in motor neurons, disrupting normal cellular function.
The energy failure component of ALS pathology made creatine a logical candidate for neuroprotection research.
The Rationale for Creatine in ALS
Wallimann et al. (2011) described the creatine kinase/phosphocreatine system as central to cellular energy homeostasis, with pleiotropic protective effects including antioxidant properties and mitochondrial membrane stabilization (T et al., 2011) .
The rationale for testing creatine in ALS was compelling:
Energy buffering — by increasing phosphocreatine reserves in motor neurons, creatine could potentially maintain ATP levels during periods of mitochondrial stress, extending cell survival.
Mitochondrial protection — creatine’s interaction with the mitochondrial permeability transition pore could prevent the catastrophic mitochondrial failure that leads to motor neuron death.
Antioxidant effects — creatine’s direct antioxidant properties could help counter the oxidative stress that damages motor neurons in ALS.
Anti-excitotoxic effects — by maintaining cellular energy levels, creatine could help motor neurons maintain the membrane potential needed to resist glutamate excitotoxicity.
Sullivan et al. (2000) had demonstrated creatine’s neuroprotective potential in traumatic brain injury models, showing up to 50% reduction in brain damage (PG et al., 2000) . This added to the optimism about creatine’s potential in neurodegenerative disease.
Preclinical Results
Animal studies of creatine in ALS models produced genuinely encouraging results. Studies using the SOD1-G93A transgenic mouse model (the most widely used ALS model) demonstrated:
- Delayed disease onset — creatine supplementation pushed back the age at which motor symptoms first appeared
- Slowed progression — the rate of motor function decline was reduced in creatine-treated mice
- Improved survival — creatine-supplemented mice lived longer than untreated controls
- Motor neuron preservation — histological analysis showed better motor neuron survival in treated animals
These preclinical results generated significant scientific interest and provided the rationale for proceeding to human clinical trials.
Human Clinical Trial Results
Despite the promising preclinical data, multiple large human clinical trials of creatine in ALS patients produced disappointing results:
The primary findings: Large, well-designed randomized controlled trials of creatine supplementation in ALS patients did not show significant benefits in terms of disease progression, muscle function, or survival compared to placebo.
Why the disconnect? Several factors may explain the gap between preclinical promise and clinical outcomes:
Timing — in animal studies, creatine was given before or at the earliest stages of disease. In human trials, patients were enrolled after clinical diagnosis, by which point substantial motor neuron loss had already occurred. Creatine may need to be present before the energy crisis peaks to be protective.
Dose and brain penetration — the doses achievable in human brain tissue may have been insufficient to replicate the neuroprotective concentrations achieved in smaller animal models. The blood-brain barrier limits creatine transport.
Disease complexity — ALS involves multiple pathological mechanisms beyond energy failure. Addressing only the energy component may be insufficient to alter the disease course.
Species differences — mouse models of ALS, while useful, do not perfectly replicate the human disease. Many compounds that show efficacy in ALS mice have failed in human trials.
Lessons from ALS Research
The creatine-ALS research program, while ultimately negative for clinical efficacy, provided valuable insights:
Safety confirmation — creatine supplementation was well-tolerated in ALS patients, even in this vulnerable population with progressive disease. This contributed to the extensive safety database that supports creatine’s general use.
Translational challenges — the ALS experience highlighted the difficulty of translating neuroprotective strategies from animal models to human disease, a challenge that extends far beyond creatine.
Mechanistic understanding — the research deepened our understanding of the creatine kinase system’s role in neuronal energy metabolism and its limitations in the context of advanced neurodegenerative disease.
Roschel et al. (2021) reviewed the ALS evidence as part of their comprehensive assessment of creatine and brain health, noting both the scientific rationale and the clinical limitations (H et al., 2021) . The ISSN position stand acknowledges the broader neuroprotective potential of creatine while recognizing the current limitations of clinical evidence in neurodegenerative diseases (RB et al., 2017) .
Current Status and Future Directions
Creatine is not recommended as a treatment for ALS. However, the research has not been entirely abandoned:
- Combination approaches — using creatine alongside other neuroprotective agents — are being explored
- Earlier intervention strategies — supplementing high-risk individuals before clinical disease onset — may be more effective
- Biomarker-guided approaches — using brain imaging and genetic testing to identify patients most likely to respond — could improve trial design
Malaysian Context
While ALS is rare in Malaysia as elsewhere, the condition affects families across the country. The Malaysian Motor Neurone Disease Association provides support and resources for affected individuals and their families.
For the general Malaysian population, the ALS research experience provides an important lesson: creatine’s excellent safety profile has been confirmed even in vulnerable patient populations. For healthy individuals seeking cognitive or physical performance benefits, creatine at standard doses (5g/day) remains one of the most well-supported supplements available.
Creatine monohydrate is available throughout Malaysia via Shopee, Lazada, and local retailers, with halal-certified options from approximately RM40.
Sources & References
This article cites Roschel et al. (2021), Wallimann et al. (2011), Sullivan et al. (2000), Avgerinos et al. (2018), and the ISSN Position Stand (Kreider et al., 2017). Full citations are available in our Research Library.